Arecor Therapeutics (LON:AREC) Posts Quarterly Earnings Results

Arecor Therapeutics (LON:AREC) released its earnings results on Thursday. The company reported GBX (7) EPS for the quarter, Digital Look Earnings reports. Arecor Therapeutics had a negative return on equity of 118.67% and a negative net margin of 176.89%.

Arecor Therapeutics Price Performance

Shares of LON AREC traded up GBX 14.30 during midday trading on Thursday, hitting GBX 86.80. The company had a trading volume of 132,247 shares, compared to its average volume of 35,933. The company has a quick ratio of 6.24, a current ratio of 1.37 and a debt-to-equity ratio of 5.51. Arecor Therapeutics has a twelve month low of GBX 35.40 and a twelve month high of GBX 100. The business has a 50-day simple moving average of GBX 63.89 and a two-hundred day simple moving average of GBX 50.04. The firm has a market capitalization of £32.77 million, a price-to-earnings ratio of -280.00 and a beta of -0.18.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products.